Business Description
Larimar Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US5171251003
Total Employee Number:
71Description
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 53.03 | |||||
Equity-to-Asset | 0.76 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -18.7 | |||||
3-Year EPS without NRI Growth Rate | -18.3 | |||||
3-Year FCF Growth Rate | -13 | |||||
3-Year Book Growth Rate | -28.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 33.14 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 47.57 | |||||
9-Day RSI | 44.79 | |||||
14-Day RSI | 44.18 | |||||
3-1 Month Momentum % | -36.92 | |||||
6-1 Month Momentum % | -3.57 | |||||
12-1 Month Momentum % | 2.27 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.29 | |||||
Quick Ratio | 4.29 | |||||
Cash Ratio | 4.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -24.3 | |||||
Shareholder Yield % | -30.27 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -129.84 | |||||
ROA % | -96.31 | |||||
ROIC % | -3297.87 | |||||
3-Year ROIIC % | 10057.03 | |||||
ROC (Joel Greenblatt) % | -5801.29 | |||||
ROCE % | -131.54 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.24 | |||||
Price-to-Tangible-Book | 2.24 | |||||
EV-to-EBIT | -0.91 | |||||
EV-to-EBITDA | -0.91 | |||||
EV-to-FCF | -1.2 | |||||
| Price-to-Net-Current-Asset-Value | 2.29 | |||||
| Price-to-Net-Cash | 2.37 | |||||
Earnings Yield (Greenblatt) % | -109.89 | |||||
FCF Yield % | -37.12 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Larimar Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.766 | ||
| Beta | 0.7975 | ||
| 3-Year Sharpe Ratio | 0.36 | ||
| 3-Year Sortino Ratio | 0.68 | ||
| Volatility % | 86.27 | ||
| 14-Day RSI | 44.18 | ||
| 14-Day ATR (€) | 0.135385 | ||
| 20-Day SMA (€) | 2.966 | ||
| 12-1 Month Momentum % | 2.27 | ||
| 52-Week Range (€) | 2.36 - 5.25 | ||
| Shares Outstanding (Mil) | 103.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Larimar Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Larimar Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 120 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 37 days | ||
| Nomlabofusp Program for Friedreich’s Ataxia | 2026-06-29 07:45 | 3.02 (+0.00%) | ||
| General meeting for 2026 | 2026-05-19 08:00 | 3.00 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 3.48 (+1.16%) | ||
| Annual report for 2025 | 2026-03-19 | 3.84 (+2.67%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-19 | 3.84 (+2.67%) | ||
| The Citizens Life Sciences Conference | 2026-03-11 16:00 | 5.00 (+0.00%) | ||
| Leerink Partners Global Healthcare Conference | 2026-03-10 08:40 | 4.34 (+0.00%) | ||
| 44(th) Annual J.P. Morgan Healthcare Conference | 2026-01-14 09:00 | 2.72 (+0.00%) |
Show
Entries
Larimar Therapeutics Inc Frequently Asked Questions
What is Larimar Therapeutics Inc(FRA:ZA71)'s stock price today?
The current price of FRA:ZA71 is €2.82. The 52 week high of FRA:ZA71 is €5.25 and 52 week low is €2.36.
When is next earnings date of Larimar Therapeutics Inc(FRA:ZA71)?
The next earnings date of Larimar Therapeutics Inc(FRA:ZA71) is 2026-08-14 Est..
Does Larimar Therapeutics Inc(FRA:ZA71) pay dividends? If so, how much?
Larimar Therapeutics Inc(FRA:ZA71) does not pay dividend.
Press Release
Articles on Larimar Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers